Erythema nodosum and Hodgkin's disease

Taillan, B.; Ferrari, Émile; Fuzibet, J.G.; Vinti, H.; Pesce, A.; Dujardin, P

doi:10.1007/bf02114402

Cited by 9 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most cases EN preceded the occurrence of HD by 1–12 months; 4,5 , 7,11 , 13,14 however, it preceded HD by 24 months in one case, 12 and occurred 3 years after the diagnosis of the malignant disease in another 6 . Skin nodules developed rarely during the remission phases of of HD 8,10 . Leukocytoclastic vasculitis was associated in two cases 14…”

Section: Reportmentioning

confidence: 96%

See 1 more Smart Citation

Erythema nodosum and Hodgkin's disease

Bonci¹,

Lernia²,

Merli

et al. 2001

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

Section: Reportmentioning

confidence: 96%

“…Lymphomas can represent a rare cause of EN 1–3 . The first report of EN occurring as a manifestation of HD appeared in 1906 4 and 15 other cases have been reported in the literature 4–14 …”

Section: Reportmentioning

confidence: 99%

Erythema nodosum and Hodgkin's disease

Bonci¹,

Lernia²,

Merli

et al. 2001

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Therefore, drug-related was considered the most likely cause of EN, and the suspected drug was olaparib, which was started four days before onset. It was reported that the relapse of malignancy might induce EN, although the patient’s disease status was relatively stable in this case [ 16 ]. Erythema induratum of Bazin is included in the differential diagnosis of EN.…”

Section: Discussionmentioning

confidence: 81%

Development of Erythema Nodosum After Olaparib Treatment in a Patient With Recurrent Breast Cancer and BRCA2 Mutation: A Case Report

Saito,

Fujii,

Banno

et al. 2023

Cureus

View full text Add to dashboard Cite

BRCA1 and 2 mutations are known to be associated with breast cancer, and olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been shown to be effective in cells carrying these mutations in some studies. Erythema nodosum (EN), which is one adverse event of olaparib and is discussed in this paper, is considered to be a very rare condition. A 69-year-old female patient underwent left breast conservative surgery with axillary lymph node dissection for left invasive ductal breast cancer (stage IIB). Her family history included a sister who developed ovarian cancer at age 63. Five years postoperatively, systemic metastases were discovered in the lung, bone, hilar, and poststernal lymph nodes. The surgically removed metastatic lung nodule was diagnosed as an estrogen receptor (ER)-positive, progesterone receptor (PgR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative metastatic adenocarcinoma of breast cancer origin. And germline mutations of BRCA1/ 2 were assessed using BRACAnalysis CDx ® (Myriad Genetics, Salt Lake City, UT, USA), and BRCA2 1241 delC was identified as a deleterious mutation. Oral administration of olaparib was started. On day 4 of this treatment, numerous erythematous plaques characterized by intense tenderness and infiltration appeared on the extensor surfaces of the bilateral lower legs. On the basis of the clinical findings, the lesions were diagnosed as EN. Oral prednisolone was started at the same time as olaparib discontinuation, and the EN lesions disappeared in one week. EN is an inflammatory lesion characterized by tender subcutaneous induration with a flushed surface, predominantly on the bilateral lower legs. EN occurring after olaparib administration is considered to be very rare. This article describes such a case and reviews the relevant literature.

show abstract

“…Patients did not respond to prednisone. Finally, in addition to long noted associations, erythema nodosum has recently been reported with Hodgkin's disease [66].…”

Section: Nonarticular Rheumatic Syndromesmentioning

confidence: 98%